Absorption, distribution and excretion of the new thienopyridine agent prasugrel in rats

References

• Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, Jones RH, Kereiakes D, Kupersmith J, Levin TN, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction—summary article: A report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients with Unstable Angina). Journal of the American College of Cardiology 2002; 40: 1366–1374
   PubMed Web of Science ®Google Scholar
• Farid NA, Smith RL, Gillespie TA, Rash TJ, Blair PE, Kurihara A, Goldberg MJ. The disposition of prasugrel, a novel thienopyridine in humans. Drug Metabolism and Dispositon. 2007a, [Epub ahead of print]
   Google Scholar
• Farid NA, McIntosh M, Garofolo F, Wong E, Shwajch A, Kennedy M, Young M, Sarkar P, Kawabata K, Takahashi M, et al. Determination of the active and inactive metabolites of prasugrel in human plasma by liquid chromatography/tandem mass spectrometry. Rapid Communications in Mass Spectrometry 2007b; 21: 169–179
   PubMed Web of Science ®Google Scholar
• Godard P, Zini R, Metay A, Tillement JP. The fate of ticlopidine in the organism. II. Distribution and elimination of ticlopidine 14C after a single oral administration in the rat. European Journal of Drug Metabolism and Pharmacokinetics 1979; 4: 133–138
   PubMedGoogle Scholar
• Jernberg T, Payne CD, Winters KJ, Darstein C, Brandt JT, Jakubowski JA, Naganuma H, Siegbahn A, Wallentin L. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. European Heart Journal 2006; 27: 1166–1173
   PubMed Web of Science ®Google Scholar
• Kazui M, Ishizuka T, Yamamura N, Kurihara A, Naganuma H, Iwabuchi H, Takahashi M, Kawabata K, Yoneda K, Kita J, et al. Mechanism for production of pharmacologically active metabolites of CS-747, a new pro-drug ADP-receptor antagonist [abstract]. Thrombosis and Haemostasis (Suppl). 2001, Abstract P1916. Retrieved [2 February, 2007] from http://www.cartesian-secure.com/isth2001/iAbstract/html/absP1916.html
   Google Scholar
• Kurihara A, Hagihara K, Kazui M, Ozeki T, Farid NA, Ikeda T. In vitro metabolism of antiplatelet agent clopidogrel: cytochrome P450 isoforms responsible for two oxidation steps involved in the active metabolite formation. Drug Metabolism Reviews 2005; 37(S2)99
   Google Scholar
• Lins R, Broekhuysen J, Necciari J, Deroubaix X. Pharmacokinetic profile of 14C-labeled clopidogrel. Seminars in Thrombosis and Hemostasis 1999; 25(Suppl 2)29–33
   PubMed Web of Science ®Google Scholar
• Niitsu Y, Jakubowski JA, Sugidachi A, Asai F. Pharmacology of CS-747 (Prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y(12) receptor antagonist activity. Seminars in Thrombosis and Hemostasis 2005; 31: 184–194
   PubMed Web of Science ®Google Scholar
• Rehmel JL, Eckstein JA, Farid NA, Heim JB, Kasper SC, Kurihara A, Wrighton SA, Ring BJ. Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes p450. Drug Metabolism and Disposition 2006; 34: 600–607
   PubMed Web of Science ®Google Scholar
• Savi P, Pereillo JM, Uzabiaga MF, Combalbert J, Picard C, Maffrand JP, Pascal M, Herbert JM. Identification and biological activity of the active metabolite of clopidogrel. Thrombosis and Haemostasis 2000; 84: 891–896
   PubMed Web of Science ®Google Scholar
• Savi P, Herbert JM. Clopidogrel and ticlopidine: P2Y(12) adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Seminars in Thrombosis and Hemostasis 2005; 31: 174–183
   PubMed Web of Science ®Google Scholar
• Schulman SP. Antiplatelet therapy in non-ST-segment elevation acute coronary syndromes. Journal of the American Medical Association 2004; 292: 1875–1882
   Google Scholar
• Smith RL, Gillespie TA, Rash TJ, Kurihara A, Farid NA. Disposition and Matabolic fate of prasugrel in mice, rats, and dogs. Xenobiotica 2007, (In press)
   Google Scholar
• Smith Jr SC, Feldman TE, Hirshfeld Jr JW, Jacobs AK, Kern MJ, King 3rd SB, Morrison DA, O'Neil W, Schaff HV, Whitlow PL, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006; 113: e166–e286
   PubMed Web of Science ®Google Scholar
• Sugidachi A, Asai F, Ogawa T, Inoue T, Koike H. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. British Journal of Pharmacology 2000; 29: 1439–1446
   Google Scholar
• Takahashi M, Pang H, Kikuchi A, Kawabata K, Kurihara A, Farid NA, Ikeda T. Stabilization of the clopidogrel active metabolite in whole blood and its assay in human plasma by LC-MS/MS [abstract]. Paper presented at the meeting of the American Society for Mass Spectrometry. Seattle, WAUSA 28 May–1 June, 2006, 2006
   Google Scholar
• Yoneda K, Iwamura R, Kishi H, Mizukami Y, Mogami K, Kobayashi S. Identification of the active metabolite of ticlopidine from rat in vitro metabolites. British Journal of Pharmacology 2004; 142: 551–557
   PubMed Web of Science ®Google Scholar